Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI376 Plus Rituximab in Untreated Indolent Lymphoma
NCT05073250Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of parsaclisib in follicular lymphoma (FL) and marginal zone lymphoma (MZL), sponsored by Chinese PLA General Hospital. Primary endpoint: Complete Response Rate at 6 months. Status: unknown.
02
Drugs
parsaclisib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT05073250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05073250.